OS Therapies to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit
OS Therapies (NYSE American: OSTX), a clinical-stage immunotherapy and Antibody Drug Conjugate biopharmaceutical company, has announced its participation in the 2024 Maxim Healthcare Virtual Summit. The company's CEO, Paul Romness, will be presenting in a fireside chat during the event.
Key details of the presentation:
- Event: Fireside Chat at 2024 Maxim Healthcare Virtual Summit
- Date: Thursday, October 17, 2024
- Time: 3:00 PM ET
The summit is scheduled to take place virtually from October 15 to 17, 2024. Interested parties can access the webcast of the fireside chat through the provided link: https://m-vest.com/events/healthcare-10152024
- None.
- None.
Event: |
Fireside Chat at 2024 Maxim Healthcare Virtual Summit |
Date: |
Thursday, October 17, 2024 |
Time: |
3:00 PM ET |
Webcast: |
About OS Therapies
OS Therapies is a clinical stage oncology company focused on the identification, development and commercialization of treatments for Osteosarcoma (OS) and other solid tumors. OST-HER2, the Company’s lead asset, is an immunotherapy leveraging the immune-stimulatory effects of Listeria bacteria to initiate a strong immune response targeting the HER2 protein. The Company has completed enrollment for a 41-patient Phase 2b clinical trial of OST-HER2 in resected, recurrent osteosarcoma, with results expected in the fourth quarter of 2024. OST-HER2 has completed a Phase 1 clinical study primarily in breast cancer patients, in addition to showing strong preclinical efficacy data in various models of breast cancer. OST-HER2 has been conditionally approved by the
Forward-Looking Statements
Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute forward-looking statements within the meaning of the federal securities laws. These forward-looking statements and terms such as “anticipate,” “expect,” “intend,” “may,” “will,” “should” or other comparable terms involve risks and uncertainties because they relate to events and depend on circumstances that will occur in the future. Those statements include statements regarding the intent, belief or current expectations of OS Therapies and members of its management, as well as the assumptions on which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, including those described under the section entitled “Risk Factors” of our Registration Statement on Form S-1 declared effective by the Securities and Exchange Commission (the “SEC”) on July 31, 2024, as well as any of our periodic reports filed with the SEC, and that actual results may differ materially from those indicated by such forward-looking statements. Any forward-looking statements contained in this press release speak only as of the date hereof, and, except as required by the federal securities laws, OS Therapies specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241017497143/en/
Corporate and Media Contact:
Jack Doll
410-297-7793
Irpr@ostherapies.com
Source: OS Therapies
FAQ
When is OS Therapies (OSTX) presenting at the 2024 Maxim Healthcare Virtual Summit?
Who will be representing OS Therapies (OSTX) at the 2024 Maxim Healthcare Virtual Summit?
What type of presentation will OS Therapies (OSTX) be giving at the 2024 Maxim Healthcare Virtual Summit?
How can I access the OS Therapies (OSTX) presentation at the 2024 Maxim Healthcare Virtual Summit?
What are the dates for the 2024 Maxim Healthcare Virtual Summit where OS Therapies (OSTX) is presenting?
